Objective: To establish an optimized aqueous extraction process for polysaccharides from Physalis alkekengi L. peel and to preliminarily explore its in vitro anti-inflammatory activity against colorectal cancer SW620 cells. Methods: A single-factor test combined with orthogonal test analysis was used to evaluate the effects of the material-to-liquid ratio, extraction temperature, and extraction time on the yield of polysaccharides from Physalis alkekengi L. peel. The antioxidant activity of the polysaccharides was assessed by analyzing their free radical scavenging ability in vitro, and the anti-inflammatory effect was evaluated using SW620 cells. Results: The optimal extraction conditions were a material-to-liquid ratio of m(g):V(mL) = 1:30, an extraction temperature of 100°C, and an extraction time of 40 minutes, with a predicted polysaccharide yield of 25.7%. The polysaccharides from Physalis peruviana peel effectively scavenged DPPH, superoxide anion, and hydroxyl radicals. After treatment with Physalis peruviana polysaccharides, the levels of IL-1β, IL-18, and TNF-α in the cell culture medium were significantly reduced, and the phosphorylation level of P65 protein in SW620 cells was decreased. Conclusion: This extraction method is stable and reliable, and the prepared Physalis alkekengi L. polysaccharides exhibit significant in vitro antioxidant and anti-inflammatory activities. This study provides a theoretical basis for developing drugs for the prevention and treatment of colorectal cancer.
{"title":"Optimization of Polysaccharides Extraction from Physalis alkekengi L. Peel and Its Effect on the Expression of Inflammation-Related Proteins in SW620 Cells","authors":"Dan Shao, Chengxin Hao, Yubi Mei, Jiaxin Xu, Tianjiao Wang, Wei Yang, Jiamei Wu","doi":"10.26689/par.v8i4.7906","DOIUrl":"https://doi.org/10.26689/par.v8i4.7906","url":null,"abstract":"Objective: To establish an optimized aqueous extraction process for polysaccharides from Physalis alkekengi L. peel and to preliminarily explore its in vitro anti-inflammatory activity against colorectal cancer SW620 cells. Methods: A single-factor test combined with orthogonal test analysis was used to evaluate the effects of the material-to-liquid ratio, extraction temperature, and extraction time on the yield of polysaccharides from Physalis alkekengi L. peel. The antioxidant activity of the polysaccharides was assessed by analyzing their free radical scavenging ability in vitro, and the anti-inflammatory effect was evaluated using SW620 cells. Results: The optimal extraction conditions were a material-to-liquid ratio of m(g):V(mL) = 1:30, an extraction temperature of 100°C, and an extraction time of 40 minutes, with a predicted polysaccharide yield of 25.7%. The polysaccharides from Physalis peruviana peel effectively scavenged DPPH, superoxide anion, and hydroxyl radicals. After treatment with Physalis peruviana polysaccharides, the levels of IL-1β, IL-18, and TNF-α in the cell culture medium were significantly reduced, and the phosphorylation level of P65 protein in SW620 cells was decreased. Conclusion: This extraction method is stable and reliable, and the prepared Physalis alkekengi L. polysaccharides exhibit significant in vitro antioxidant and anti-inflammatory activities. This study provides a theoretical basis for developing drugs for the prevention and treatment of colorectal cancer.","PeriodicalId":20511,"journal":{"name":"Proceedings of Anticancer Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141922681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: To analyze the therapeutic effect of tislelizumab combined with chemotherapy in patients with stage IIIb–IV non-small cell lung cancer (NSCLC). Methods: A total of 50 patients with stage IIIb–IV NSCLC admitted between January 2022 and January 2024 were randomly divided into two groups using a random number table. The observation group included 25 cases treated with tislelizumab combined with chemotherapy, while the reference group included 25 cases treated with conventional chemotherapy. The clinical control rate, adverse reaction rate, tumor markers, immune function indicators, and quality of life scores were compared between the two groups. Results: The observation group had a higher clinical control rate and a lower adverse reaction rate compared to the reference group (P < 0.05). Before treatment, there were no significant differences in tumor markers, immune function indicators, and quality of life scores between the two groups (P > 0.05). Three months after treatment, the tumor marker levels in the observation group were lower than those in the reference group. Except for CD8+, all immune function indicators in the observation group were higher than those in the reference group, and the quality-of-life scores in the observation group were higher than those in the reference group (P < 0.05). Conclusion: Implementing tislelizumab combined with chemotherapy in patients with stage IIIb–IV NSCLC can improve the clinical control rate, reduce the adverse reaction rate, lower tumor marker levels, protect immune function, and improve quality of life.
{"title":"Clinical Effect of Tislelizumab Combined with Chemotherapy in the Treatment of Stage IIIb–IV Non-Small Cell Lung Cancer","authors":"Jie Jiang","doi":"10.26689/par.v8i4.7901","DOIUrl":"https://doi.org/10.26689/par.v8i4.7901","url":null,"abstract":"Objective: To analyze the therapeutic effect of tislelizumab combined with chemotherapy in patients with stage IIIb–IV non-small cell lung cancer (NSCLC). Methods: A total of 50 patients with stage IIIb–IV NSCLC admitted between January 2022 and January 2024 were randomly divided into two groups using a random number table. The observation group included 25 cases treated with tislelizumab combined with chemotherapy, while the reference group included 25 cases treated with conventional chemotherapy. The clinical control rate, adverse reaction rate, tumor markers, immune function indicators, and quality of life scores were compared between the two groups. Results: The observation group had a higher clinical control rate and a lower adverse reaction rate compared to the reference group (P < 0.05). Before treatment, there were no significant differences in tumor markers, immune function indicators, and quality of life scores between the two groups (P > 0.05). Three months after treatment, the tumor marker levels in the observation group were lower than those in the reference group. Except for CD8+, all immune function indicators in the observation group were higher than those in the reference group, and the quality-of-life scores in the observation group were higher than those in the reference group (P < 0.05). Conclusion: Implementing tislelizumab combined with chemotherapy in patients with stage IIIb–IV NSCLC can improve the clinical control rate, reduce the adverse reaction rate, lower tumor marker levels, protect immune function, and improve quality of life.","PeriodicalId":20511,"journal":{"name":"Proceedings of Anticancer Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141922266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chengrui Peng, Linfei Wu, Xiaofang Yang, Hanyun Yao, Yan Xie
Objective: To analyze the expression and clinical significance of the zinc finger protein ZNF207 gene in liver hepatocellular carcinoma (LIHC) based on The Cancer Genome Atlas (TCGA) database. Methods: The mRNA sequencing data of 371 cases of primary liver cancer, 50 cases of normal tissues, and 3 cases of recurrent liver cancer were downloaded from the TCGA database. The corresponding clinical information of the 371 cases of hepatocellular carcinoma was subsequently analyzed. The difference in ZNF207 expression between normal and tumor tissues was analyzed using the UALCAN online database. The impact of ZNF207 expression on survival prognosis was assessed using the Kaplan-Meier method in R software. The GO and KEGG pathways of ZNF207 were analyzed. The Cox proportional hazards model was used to evaluate the prognostic factors of patients with LIHC. RT-qPCR was employed to verify the expression of ZNF207 in LIHC cells. Results: ZNF207 was highly expressed in LIHC tissues and HepG2 cells, with a significant difference (P < 0.05). Multivariate Cox regression analysis revealed that patients with high ZNF207 expression had a significantly shorter overall survival time compared to those with low ZNF207 expression (HR = 1.466, 95% CI: 1.011–2.126, P < 0.05). GO enrichment analysis suggested that ZNF207 may influence the onset and progression of hepatocellular carcinoma by regulating mRNA splicing and mRNA transcription processing through the spliceosome. KEGG pathway enrichment analysis indicated that ZNF207 might affect the onset and progression of hepatocellular carcinoma through mitophagy, mRNA surveillance, homologous recombination, spliceosome, and nuclear-cytoplasmic transport. Conclusion: The expression of ZNF207 may be an independent predictor of the prognosis of patients with LIHC and could influence the development of hepatocellular carcinoma through various gene functions and pathways. It has the potential to serve as a novel molecular marker for predicting the prognosis of hepatocellular carcinoma.
{"title":"The Role of ZNF207 in Liver Hepatocellular Carcinoma: Expression Analysis and Prognostic Implications","authors":"Chengrui Peng, Linfei Wu, Xiaofang Yang, Hanyun Yao, Yan Xie","doi":"10.26689/par.v8i4.7894","DOIUrl":"https://doi.org/10.26689/par.v8i4.7894","url":null,"abstract":"Objective: To analyze the expression and clinical significance of the zinc finger protein ZNF207 gene in liver hepatocellular carcinoma (LIHC) based on The Cancer Genome Atlas (TCGA) database. Methods: The mRNA sequencing data of 371 cases of primary liver cancer, 50 cases of normal tissues, and 3 cases of recurrent liver cancer were downloaded from the TCGA database. The corresponding clinical information of the 371 cases of hepatocellular carcinoma was subsequently analyzed. The difference in ZNF207 expression between normal and tumor tissues was analyzed using the UALCAN online database. The impact of ZNF207 expression on survival prognosis was assessed using the Kaplan-Meier method in R software. The GO and KEGG pathways of ZNF207 were analyzed. The Cox proportional hazards model was used to evaluate the prognostic factors of patients with LIHC. RT-qPCR was employed to verify the expression of ZNF207 in LIHC cells. Results: ZNF207 was highly expressed in LIHC tissues and HepG2 cells, with a significant difference (P < 0.05). Multivariate Cox regression analysis revealed that patients with high ZNF207 expression had a significantly shorter overall survival time compared to those with low ZNF207 expression (HR = 1.466, 95% CI: 1.011–2.126, P < 0.05). GO enrichment analysis suggested that ZNF207 may influence the onset and progression of hepatocellular carcinoma by regulating mRNA splicing and mRNA transcription processing through the spliceosome. KEGG pathway enrichment analysis indicated that ZNF207 might affect the onset and progression of hepatocellular carcinoma through mitophagy, mRNA surveillance, homologous recombination, spliceosome, and nuclear-cytoplasmic transport. Conclusion: The expression of ZNF207 may be an independent predictor of the prognosis of patients with LIHC and could influence the development of hepatocellular carcinoma through various gene functions and pathways. It has the potential to serve as a novel molecular marker for predicting the prognosis of hepatocellular carcinoma.","PeriodicalId":20511,"journal":{"name":"Proceedings of Anticancer Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141923619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xinyu Zheng, Xiaomeng Chen, Xingzhou Xia, Wenzhen Wang, Qian Liu
Objective: Investigate the cytotoxic effect of CAR-NK cells targeting CEA on colorectal cancer cells with positive CEA expression. Methods: The mRNA and protein levels of CEA in different CRC cell lines were detected by qRT-PCR and Western blot analysis. Lentiviral transduction was used to construct CAR-NK cells and empty vector CON-NK cells targeting CEA. Fluorescence microscopy and WB were used to determine whether the cells successfully constructed and expressed CAR structures. The effector NK cells were co-cultured with target cells, and the levels of LDH, IFN-γ, and GM-CSF were detected. The killing rate of effector cells was calculated, and the release of cytokines during the killing of target cells by different effector cells was compared. Results: The expression level of CEA in colorectal cancer patients was significantly higher than that in normal samples and other tumor samples, and the prognosis survival time of patients with high CEA expression was lower than that of CRC patients with low or no CEA expression (P < 0.05). The CEA expression of the HT29 cell line was significantly higher than that of the SW1116 cell line at both the mRNA and protein levels. CEA-CAR-NK92 cells and CON-NK92 cells expressed green fluorescence under a microscope, and WB results showed that CEA-CAR-NK92 cells successfully expressed the CAR structure. Compared with CON-NK92 cells and NK92 cells, CEA-CAR-NK92 cells effectively killed HT29 cells (P < 0.05). CEA-CAR-NK92 cells secreted a large amount of IFN-γ and GM-CSF during the killing of HT29 cells, while the cytokine secretion of CON-NK92 cells and NK92 cells was not significant (P < 0.05). Conclusion: CAR-NK92 cells targeting CEA can effectively kill CEA-positive colorectal cancer cells.
目的研究靶向 CEA 的 CAR-NK 细胞对 CEA 阳性表达的结直肠癌细胞的细胞毒作用。方法通过 qRT-PCR 和 Western 印迹分析检测不同 CRC 细胞系中 CEA 的 mRNA 和蛋白水平。慢病毒转导用于构建靶向 CEA 的 CAR-NK 细胞和空载体 CON-NK 细胞。荧光显微镜和WB检测细胞是否成功构建并表达CAR结构。将效应 NK 细胞与靶细胞共培养，检测 LDH、IFN-γ 和 GM-CSF 的水平。计算效应细胞的杀伤率，并比较不同效应细胞杀伤靶细胞过程中细胞因子的释放情况。结果结直肠癌患者 CEA 的表达水平明显高于正常样本和其他肿瘤样本，且 CEA 高表达患者的预后生存时间低于 CEA 低表达或无表达的 CRC 患者（P < 0.05）。HT29 细胞株的 CEA 表达在 mRNA 和蛋白水平上都明显高于 SW1116 细胞株。CEA-CAR-NK92细胞和CON-NK92细胞在显微镜下均表达绿色荧光，WB结果显示CEA-CAR-NK92细胞成功表达了CAR结构。与 CON-NK92 细胞和 NK92 细胞相比，CEA-CAR-NK92 细胞能有效杀死 HT29 细胞（P < 0.05）。在杀死 HT29 细胞的过程中，CEA-CAR-NK92 细胞分泌了大量的 IFN-γ 和 GM-CSF，而 CON-NK92 细胞和 NK92 细胞的细胞因子分泌量并不显著（P < 0.05）。结论靶向CEA的CAR-NK92细胞能有效杀死CEA阳性结直肠癌细胞。
{"title":"Targeted Therapy of CEA-CAR-NK Cells Against Colorectal Cancer Cells","authors":"Xinyu Zheng, Xiaomeng Chen, Xingzhou Xia, Wenzhen Wang, Qian Liu","doi":"10.26689/par.v8i4.7607","DOIUrl":"https://doi.org/10.26689/par.v8i4.7607","url":null,"abstract":"Objective: Investigate the cytotoxic effect of CAR-NK cells targeting CEA on colorectal cancer cells with positive CEA expression. Methods: The mRNA and protein levels of CEA in different CRC cell lines were detected by qRT-PCR and Western blot analysis. Lentiviral transduction was used to construct CAR-NK cells and empty vector CON-NK cells targeting CEA. Fluorescence microscopy and WB were used to determine whether the cells successfully constructed and expressed CAR structures. The effector NK cells were co-cultured with target cells, and the levels of LDH, IFN-γ, and GM-CSF were detected. The killing rate of effector cells was calculated, and the release of cytokines during the killing of target cells by different effector cells was compared. Results: The expression level of CEA in colorectal cancer patients was significantly higher than that in normal samples and other tumor samples, and the prognosis survival time of patients with high CEA expression was lower than that of CRC patients with low or no CEA expression (P < 0.05). The CEA expression of the HT29 cell line was significantly higher than that of the SW1116 cell line at both the mRNA and protein levels. CEA-CAR-NK92 cells and CON-NK92 cells expressed green fluorescence under a microscope, and WB results showed that CEA-CAR-NK92 cells successfully expressed the CAR structure. Compared with CON-NK92 cells and NK92 cells, CEA-CAR-NK92 cells effectively killed HT29 cells (P < 0.05). CEA-CAR-NK92 cells secreted a large amount of IFN-γ and GM-CSF during the killing of HT29 cells, while the cytokine secretion of CON-NK92 cells and NK92 cells was not significant (P < 0.05). Conclusion: CAR-NK92 cells targeting CEA can effectively kill CEA-positive colorectal cancer cells.","PeriodicalId":20511,"journal":{"name":"Proceedings of Anticancer Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141829182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: This study aimed to investigate the effectiveness and value of MRI and CT in the diagnosis of retroperitoneal tumours. Methods: 60 patients with retroperitoneal tumours admitted to our hospital between July 2022 and March 2023 were selected as the study subjects. All of them received MRI and CT examinations. The detection of the two examination methods was compared and analyzed using the pathological findings as the standard. Results: The detection rate of MRI (58/60, 96.67%) was significantly higher than that of CT (50/60, 83.33%), and the difference was significant (P = 0.015 < 0.05). Conclusion: Both MRI and CT have important application values in the diagnosis of retroperitoneal tumours. MRI has advantages in observing soft tissue structures, nerve tissues, etc., and can provide more detailed anatomical structure information, which can help differentiate the retroperitoneal tumours and locate them accurately. CT, on the other hand, has unique advantages in observing the skeletal structure and the density of certain tumours, etc. It can quickly obtain comprehensive imaging information, which helps to determine the extent and invasion of the tumour.
{"title":"The Value of MRI and CT in the Diagnosis of Retroperitoneal Tumours","authors":"Xinlian Jin, Ying Zhou","doi":"10.26689/par.v8i4.7518","DOIUrl":"https://doi.org/10.26689/par.v8i4.7518","url":null,"abstract":"Objective: This study aimed to investigate the effectiveness and value of MRI and CT in the diagnosis of retroperitoneal tumours. Methods: 60 patients with retroperitoneal tumours admitted to our hospital between July 2022 and March 2023 were selected as the study subjects. All of them received MRI and CT examinations. The detection of the two examination methods was compared and analyzed using the pathological findings as the standard. Results: The detection rate of MRI (58/60, 96.67%) was significantly higher than that of CT (50/60, 83.33%), and the difference was significant (P = 0.015 < 0.05). Conclusion: Both MRI and CT have important application values in the diagnosis of retroperitoneal tumours. MRI has advantages in observing soft tissue structures, nerve tissues, etc., and can provide more detailed anatomical structure information, which can help differentiate the retroperitoneal tumours and locate them accurately. CT, on the other hand, has unique advantages in observing the skeletal structure and the density of certain tumours, etc. It can quickly obtain comprehensive imaging information, which helps to determine the extent and invasion of the tumour.","PeriodicalId":20511,"journal":{"name":"Proceedings of Anticancer Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141834863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: To investigate the clinical value of immunohistochemistry (IHC) detection in the pathological diagnosis of breast cancer. Methods: Eighty breast cancer patients admitted to Baoding No. 1 Central Hospital from June 2022 to June 2023 were selected as study subjects. The samples were divided into a positive group (40 cases) and a negative group (40 cases) according to ER and PR test results. Immunohistochemistry was performed on all patients to compare the differences between the two groups in C-erbB-2 positive expression and axillary lymph node metastasis. Results: The positive expression rate of C-erbB-2 in the positive group (35.00%) was significantly lower than that in the negative group (80.00%), with a highly significant difference (P < 0.001). The axillary lymph node metastasis rate in the positive group (40.00%) was significantly lower than that in the negative group (75.00%), with a significant difference (P < 0.05). Conclusion: Immunohistochemical detection in breast cancer pathology enhances diagnostic accuracy, predicts prognosis, and supports personalized treatment by identifying ER, PR, and C-erbB-2. It is worth being widely adopted in clinical practice.
{"title":"Analysis of the Clinical Value of Immunohistochemical Testing in the Pathological Diagnosis of Breast Cancer","authors":"Qiushuang Ma, Jirui Sun, Haizhi Qiao, Xueli Wang, Jinku Zhang","doi":"10.26689/par.v8i4.7494","DOIUrl":"https://doi.org/10.26689/par.v8i4.7494","url":null,"abstract":"Objective: To investigate the clinical value of immunohistochemistry (IHC) detection in the pathological diagnosis of breast cancer. Methods: Eighty breast cancer patients admitted to Baoding No. 1 Central Hospital from June 2022 to June 2023 were selected as study subjects. The samples were divided into a positive group (40 cases) and a negative group (40 cases) according to ER and PR test results. Immunohistochemistry was performed on all patients to compare the differences between the two groups in C-erbB-2 positive expression and axillary lymph node metastasis. Results: The positive expression rate of C-erbB-2 in the positive group (35.00%) was significantly lower than that in the negative group (80.00%), with a highly significant difference (P < 0.001). The axillary lymph node metastasis rate in the positive group (40.00%) was significantly lower than that in the negative group (75.00%), with a significant difference (P < 0.05). Conclusion: Immunohistochemical detection in breast cancer pathology enhances diagnostic accuracy, predicts prognosis, and supports personalized treatment by identifying ER, PR, and C-erbB-2. It is worth being widely adopted in clinical practice.","PeriodicalId":20511,"journal":{"name":"Proceedings of Anticancer Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141662535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gastroesophageal reflux disease (GERD) is a high-incidence digestive system disease. Western medicine mainly uses drugs such as proton pump inhibitors to inhibit gastric acid secretion, but some patients are accompanied by symptoms such as non-acid reflux and gas reflux, which cannot effectively treat the disease. It is necessary to actively explore other treatment schemes. Traditional Chinese medicine (TCM) has a long history of research on gastroesophageal reflux disease, which emphasizes the treatment based on syndrome differentiation as a whole. Through the treatment of various and multi-component TCM prescriptions, the patient’s body condition can be adjusted, and the treatment effect on gastroesophageal reflux disease is reliable, which has obvious therapeutic advantages. To further clarify the treatment of gastroesophageal reflux disease, this study reviewed and analyzed the research progress of the treatment of liver disease with modified prescriptions, and the report is as follows.
{"title":"Research on the Progress of Treating Gastroesophageal Reflux Disease with Modified Classic Traditional Chinese Medicine Prescription","authors":"Haojie Fu, Yahui Huang, Xiaonan Shi","doi":"10.26689/par.v8i3.7079","DOIUrl":"https://doi.org/10.26689/par.v8i3.7079","url":null,"abstract":"Gastroesophageal reflux disease (GERD) is a high-incidence digestive system disease. Western medicine mainly uses drugs such as proton pump inhibitors to inhibit gastric acid secretion, but some patients are accompanied by symptoms such as non-acid reflux and gas reflux, which cannot effectively treat the disease. It is necessary to actively explore other treatment schemes. Traditional Chinese medicine (TCM) has a long history of research on gastroesophageal reflux disease, which emphasizes the treatment based on syndrome differentiation as a whole. Through the treatment of various and multi-component TCM prescriptions, the patient’s body condition can be adjusted, and the treatment effect on gastroesophageal reflux disease is reliable, which has obvious therapeutic advantages. To further clarify the treatment of gastroesophageal reflux disease, this study reviewed and analyzed the research progress of the treatment of liver disease with modified prescriptions, and the report is as follows.","PeriodicalId":20511,"journal":{"name":"Proceedings of Anticancer Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141266994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: To investigate the effect of TSH inhibition therapy in the postoperative management of patients with differentiated thyroid cancer. Methods: Seventy patients diagnosed with differentiated thyroid cancer were selected for the study. TSH inhibition therapy was administered to the research group, while thyroxine replacement therapy was provided to the control group during the postoperative management phase. This allowed for a comparative analysis between the two groups. Results: In comparison with the control group, the research group exhibited significant decreases in serum TSH, T3, and T4 levels after treatment, while FT4 and FT3 levels significantly increased (P < 0.05). Additionally, significant decreases in Tg, VEGF, TSGF, CD44V6, and sIL-2R levels were observed in the research group after treatment (P < 0.05). No significant differences were found in pre-treatment thyroid function between the two groups (P > 0.05). Conclusion: The application of TSH inhibition therapy in the postoperative management of patients with differentiated thyroid cancer demonstrates promising outcomes.
{"title":"Role of TSH Inhibition Therapy in the Postoperative Management of Patients with Differentiated Thyroid Cancer","authors":"Xudong Gao, Bo Zhao, Ya Su, Shenglin He","doi":"10.26689/par.v8i2.6295","DOIUrl":"https://doi.org/10.26689/par.v8i2.6295","url":null,"abstract":"Objective: To investigate the effect of TSH inhibition therapy in the postoperative management of patients with differentiated thyroid cancer. Methods: Seventy patients diagnosed with differentiated thyroid cancer were selected for the study. TSH inhibition therapy was administered to the research group, while thyroxine replacement therapy was provided to the control group during the postoperative management phase. This allowed for a comparative analysis between the two groups. Results: In comparison with the control group, the research group exhibited significant decreases in serum TSH, T3, and T4 levels after treatment, while FT4 and FT3 levels significantly increased (P < 0.05). Additionally, significant decreases in Tg, VEGF, TSGF, CD44V6, and sIL-2R levels were observed in the research group after treatment (P < 0.05). No significant differences were found in pre-treatment thyroid function between the two groups (P > 0.05). Conclusion: The application of TSH inhibition therapy in the postoperative management of patients with differentiated thyroid cancer demonstrates promising outcomes.","PeriodicalId":20511,"journal":{"name":"Proceedings of Anticancer Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140712310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: To analyze the effect of sequential early enteral nutrition in patients with gastric cancer after surgery. Methods: A total of 139 gastric cancer patients, treated between October 2021 and October 2023, were randomly selected and divided into two groups: Group A (68 cases, receiving early enteral nutrition) and Group B (71 cases, receiving sequential early enteral nutrition), using computer randomization. The effects of the interventions on both groups were compared. Results: Seven days post-operation, the levels of nutritional indicators in Group B were significantly higher than those in Group A (P < 0.05). Group B showed significantly better levels of inflammatory factors and immune factors compared to Group A seven days post-operation (P < 0.05). The postoperative complication rate in Group B was 4.23%, significantly lower than that in Group A, which was 16.18% (χ2 = 5.477, P = 0.019). Conclusion: The utilization of sequential early enteral nutrition in gastric cancer patients after surgery demonstrated notable improvements in nutritional status and inflammation markers, along with enhanced immunity, effectively reducing postoperative complications.
目的分析胃癌患者术后连续早期肠内营养的效果。方法随机选取 2021 年 10 月至 2023 年 10 月期间接受治疗的 139 例胃癌患者，将其分为两组：A组（68例，接受早期肠内营养）和B组（71例，接受连续早期肠内营养），采用计算机随机分配法。比较两组干预措施的效果。结果显示术后七天，B 组的营养指标水平明显高于 A 组（P < 0.05）。术后七天，B 组的炎症因子和免疫因子水平明显优于 A 组（P < 0.05）。B 组术后并发症发生率为 4.23%，明显低于 A 组的 16.18%（χ2 = 5.477，P = 0.019）。结论胃癌患者术后使用序贯早期肠内营养可明显改善营养状况和炎症指标，同时增强免疫力，有效减少术后并发症。
{"title":"Effect of Sequential Early Enteral Nutrition on Postoperative Rehabilitation and Complications in Gastric Cancer Patients","authors":"Dongchou Han, Qiya Feng, Yingmei Fu, Feijian Zhang, Dazhen Chen, Junmei Wu","doi":"10.26689/par.v8i2.6413","DOIUrl":"https://doi.org/10.26689/par.v8i2.6413","url":null,"abstract":"Objective: To analyze the effect of sequential early enteral nutrition in patients with gastric cancer after surgery. Methods: A total of 139 gastric cancer patients, treated between October 2021 and October 2023, were randomly selected and divided into two groups: Group A (68 cases, receiving early enteral nutrition) and Group B (71 cases, receiving sequential early enteral nutrition), using computer randomization. The effects of the interventions on both groups were compared. Results: Seven days post-operation, the levels of nutritional indicators in Group B were significantly higher than those in Group A (P < 0.05). Group B showed significantly better levels of inflammatory factors and immune factors compared to Group A seven days post-operation (P < 0.05). The postoperative complication rate in Group B was 4.23%, significantly lower than that in Group A, which was 16.18% (χ2 = 5.477, P = 0.019). Conclusion: The utilization of sequential early enteral nutrition in gastric cancer patients after surgery demonstrated notable improvements in nutritional status and inflammation markers, along with enhanced immunity, effectively reducing postoperative complications.","PeriodicalId":20511,"journal":{"name":"Proceedings of Anticancer Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140717713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: To assess the clinical effects of combining laparoscopic surgery with Modified Xiaoyan Lidan Decoction in patients diagnosed with cholecystitis and cholelithiasis. Methods: Following the guidelines of the double-blind method, 86 cases of cholecystitis with cholelithiasis were randomly divided into two groups, each comprising 43 cases. Both groups underwent laparoscopic surgery, with the observation group additionally receiving Modified Xiaoyan Lidan Decoction. A comparative analysis was conducted on clinical treatment effectiveness, general observation indicators, Traditional Chinese Medicine (TCM) syndrome scores, and the occurrence of adverse reactions between the two groups. Results: The observation group demonstrated a significantly higher overall clinical treatment effectiveness compared to the control group (P < 0.05). The clinical symptom improvement time and hospitalization time were shorter in the observation group, and the pain score and TCM syndrome score after treatment were lower than those in the control group (P < 0.05). No statistically significant difference was observed in the total reaction values (P > 0.05). Conclusion: The combined application of laparoscopic surgery and Modified Xiaoyan Lidan Decoction can enhance clinical treatment efficiency for patients with cholecystitis and cholelithiasis. It facilitates a quicker improvement in clinical symptoms without causing serious adverse reactions, suggesting its potential for widespread adoption.
{"title":"Laparoscopic Surgery and Modified Xiaoyan Lidan Decoction: An Effective Combination for Treating Cholecystitis with Cholelithiasis","authors":"Sidian Xiao","doi":"10.26689/par.v7i6.5613","DOIUrl":"https://doi.org/10.26689/par.v7i6.5613","url":null,"abstract":"Objective: To assess the clinical effects of combining laparoscopic surgery with Modified Xiaoyan Lidan Decoction in patients diagnosed with cholecystitis and cholelithiasis. Methods: Following the guidelines of the double-blind method, 86 cases of cholecystitis with cholelithiasis were randomly divided into two groups, each comprising 43 cases. Both groups underwent laparoscopic surgery, with the observation group additionally receiving Modified Xiaoyan Lidan Decoction. A comparative analysis was conducted on clinical treatment effectiveness, general observation indicators, Traditional Chinese Medicine (TCM) syndrome scores, and the occurrence of adverse reactions between the two groups. Results: The observation group demonstrated a significantly higher overall clinical treatment effectiveness compared to the control group (P < 0.05). The clinical symptom improvement time and hospitalization time were shorter in the observation group, and the pain score and TCM syndrome score after treatment were lower than those in the control group (P < 0.05). No statistically significant difference was observed in the total reaction values (P > 0.05). Conclusion: The combined application of laparoscopic surgery and Modified Xiaoyan Lidan Decoction can enhance clinical treatment efficiency for patients with cholecystitis and cholelithiasis. It facilitates a quicker improvement in clinical symptoms without causing serious adverse reactions, suggesting its potential for widespread adoption.","PeriodicalId":20511,"journal":{"name":"Proceedings of Anticancer Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138944892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：